Daptomycin
ApprovedTerminated 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Staphylococcal Skin Infections
Conditions
Staphylococcal Skin Infections
Trial Timeline
Jan 1, 2007 → —
NCT ID
NCT00463801About Daptomycin
Daptomycin is a approved stage product being developed by Novartis for Staphylococcal Skin Infections. The current trial status is terminated. This product is registered under clinical trial identifier NCT00463801. Target conditions include Staphylococcal Skin Infections.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00463801 | Approved | Terminated |
Competing Products
20 competing products in Staphylococcal Skin Infections